Search results
Health Canada has authorized these COVID-19 treatments: Remdesivir (Veklury) Nirmatrelvir and ritonavir (Paxlovid) Tocilizumab (Actemra) Each province and territory decides how to use these drugs based on their needs.
22 lut 2022 · Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial
We conducted a cost-effectiveness analysis alongside the Canadian Treatments for COVID-19 (CATCO) open-label, randomized clinical trial evaluating remdesivir. Methods: Patients with COVID-19 in Canadian hospitals from Aug. 14, 2020, to Apr. 1, 2021, were randomly assigned to receive remdesivir plus usual care versus usual care alone.
The approximate cost for a 5-day treatment course of nirmatrelvir/ritonavir is $1,300. This is an estimate because nirmatrelvir/ritonavir may be funded by select government drug programs, private insurance or paid for directly by the patient. The out-of-pocket cost to patients will depend on their drug coverage. To avoid delays in
Last updated: Sept 25, 2023. In Canada, oral nirmatrelvir/ritonavir (PaxlovidTM) and intravenous remdesivir (Veklury®) are Health Canada-approved treatments for outpatient use.
26 lis 2020 · In developing its guidelines, the WHO also looked at the cost of remdesivir and its need to be administered intravenously. Health Canada’s review takes into account our country’s health care system when assessing clinical trial data.
6 wrz 2022 · The role of remdesivir in the treatment of hospitalized patients with COVID-19 remains ill-defined. We conducted a cost-effectiveness analysis alongside the Canadian Treatments for COVID-19 (CATCO) open-label, randomized clinical trial evaluating remdesivir.
